SGLT2 inhibitors including canagliflozin (CANA) and dapagliflozin (DAPA) have been shown to slow the progression of kidney disease, as well as reduce the risk of kidney failure, as reported in the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) [13] and DAPA-CKD [14] trials respectively. The gene discussed is SLC5A2; the disease is diabetes mellitus.